CO5630029A2 - Derivados de indol e indolina sustituidos - Google Patents

Derivados de indol e indolina sustituidos

Info

Publication number
CO5630029A2
CO5630029A2 CO05118919A CO05118919A CO5630029A2 CO 5630029 A2 CO5630029 A2 CO 5630029A2 CO 05118919 A CO05118919 A CO 05118919A CO 05118919 A CO05118919 A CO 05118919A CO 5630029 A2 CO5630029 A2 CO 5630029A2
Authority
CO
Colombia
Prior art keywords
ilo
cycloalkyl
alkyl
cycloalk
cyano
Prior art date
Application number
CO05118919A
Other languages
English (en)
Inventor
Nikolay Khanzhin
Mario Rottlander
William Patrick Watson
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO5630029A2 publication Critical patent/CO5630029A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

1.- Un derivado de indol o indolina sustituido de fórmula general I en el cual la linea punteada representa un enlace opcional;R1 y R1AND#39 se seleccionan en forma independiente del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, hidroxi-alqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxi-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, halo-alqu(en/in)ilo C1-6, halo-cicloalqu(en)ilo C3-8, halo-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ciano-alqu(en/in)ilo C1-6, ciano-cicloalqu(en)ilo C3-8 y ciano-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; o R1 y R1´ junto con el átomo de carbono al cual están unidos forman un anillo saturado o insaturado de 3-8 miembros que contiene, en forma opcional, 1 o 2 heteroátomos;S es 0 o 1;U es O, NR11, S, SO2, SO2NR11, CO-O o CO-NR11; en los cuales R11 se selecciona del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; o R2 y R11 junto con el átomo de nitrógeno al cual están unidos forman un anillo saturado o insaturado de 4-8 miembros que contiene, en forma opcional, 1, 2 o 3 heteroátomos adicionales;R2 se selecciona del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, Ar, Ar-alqu(en/in)ilo C1-6, Ar-cicloalqu(en)ilo C3-8, Ar-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, acilo, hidroxialqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxicicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, halógeno, haloalqu(en/in)ilo C1-6, halo-cicloalqu(en)ilo C3-8, halocicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ciano, cianoalqu(en/in)ilo C1-6, ciano-cicloalqu(en)ilo C3-8, cianocicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, -NO2, NR10R10AND#39-alqu(en/in)ilo C1-6, NR10R10AND#39-cicloalqu(en)ilo C3-8 y NR10R10AND#39-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; en los cuales R10 y R10AND#39 se seleccionan en forma independiente del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, hidroxi-alqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxicicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ...
CO05118919A 2003-04-25 2005-11-23 Derivados de indol e indolina sustituidos CO5630029A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46538703P 2003-04-25 2003-04-25
DKPA200300631 2003-04-25

Publications (1)

Publication Number Publication Date
CO5630029A2 true CO5630029A2 (es) 2006-04-28

Family

ID=33420358

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05118919A CO5630029A2 (es) 2003-04-25 2005-11-23 Derivados de indol e indolina sustituidos

Country Status (8)

Country Link
US (1) US20060264496A1 (es)
EP (1) EP1631546A1 (es)
JP (1) JP2006524641A (es)
AU (1) AU2004233941A1 (es)
CO (1) CO5630029A2 (es)
MX (1) MXPA05010174A (es)
NO (1) NO20055562L (es)
WO (1) WO2004096767A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332851D1 (de) 2002-07-17 2010-07-15 Kyoto Pharma Ind Indolinverbindung und deren medizinische verwendung
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
EP1737414A2 (en) * 2004-01-23 2007-01-03 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
CA2641564C (en) 2006-02-07 2012-06-12 H. Lundbeck A/S Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
SG174095A1 (en) 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007325629A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
AU2008281112A1 (en) * 2007-08-01 2009-02-05 H. Lundbeck A/S Use of KCNQ potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
DK2464645T3 (en) 2009-07-27 2017-10-23 Gilead Sciences Inc CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
MX2012015096A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ion.
AU2012253653A1 (en) 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (es) 2011-07-01 2018-04-28
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2844247A4 (en) * 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN112010808B (zh) * 2019-05-31 2021-11-30 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢-1h-苯氮杂卓类化合物及其制备和应用
WO2024099269A1 (zh) * 2022-11-11 2024-05-16 华东师范大学 芳基酰胺化合物、包含其的药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234942A (en) * 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
ATE197300T1 (de) * 1995-02-02 2000-11-15 Smithkline Beecham Plc Indolderivate als 5-ht rezeptorantagoniste
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
GB9919411D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
CA2438805A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
KR100810468B1 (ko) * 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체

Also Published As

Publication number Publication date
US20060264496A1 (en) 2006-11-23
AU2004233941A1 (en) 2004-11-11
JP2006524641A (ja) 2006-11-02
EP1631546A1 (en) 2006-03-08
MXPA05010174A (es) 2005-11-08
WO2004096767A1 (en) 2004-11-11
NO20055562L (no) 2005-11-24

Similar Documents

Publication Publication Date Title
CO5630029A2 (es) Derivados de indol e indolina sustituidos
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR040030A1 (es) Moduladores biciclicos de la funcion del receptor de androgeno
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
AR049951A1 (es) Derivados de ftalazina como inhibidores de parp
AR054081A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas
AR053186A1 (es) Derivados del 1- bencil indol carboxamida
SV2009003258A (es) Nuevos derivados aminopirimidina como inhibidores de plk1
BRPI0414817A (pt) derivados de ácido indol substituìdos e seu uso como inibidores de pai-l
AR108778A1 (es) Compuestos antibacterianos
CO5680403A2 (es) Antagonistas de mchr1r
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR063128A1 (es) Compuestos de aril - indol sustituido y sus usos metabolitosde tipo quinurenina / quinurenina como agentes terapeuticos
CL2021000296A1 (es) Inhibidores tipo indol y azaindol de enzimas pad.
PE20060163A1 (es) Derivados fenilaminopropanol heterociclicos como moduladores de la reabsorcion de monoaminas
GT200700084A (es) Derivados de indanil-piperazinas, su procedimiento de preparación y las composiciones farmaceuticas que los contienen.
CO6220956A2 (es) Derivados de pirazolona como inhibidores de pde4
DOP2006000133A (es) Derivados de 4,5 diarilpiroxol, su preparación y su aplicación en terapeútica
AR052332A1 (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc
AR041080A1 (es) Compuestos de 5- croman- 5- il- etilamina substituidos y su uso para el tratamiento de glaucoma
AR054120A1 (es) Compuestos de fenilpiridilpiperazina, procedimiento de preparacion, composiciones farmaceuticas que los contienen, y usos farmacologicos como antagonistas de receptores histaminergicos h3
AR053116A1 (es) Derivados de la n-(( 4,5-difenil-2- tienil)metil)sulfonamida,su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FC Application refused